The impact of the first COVID-19 wave on office-based dermatological care in Germany: a focus on diagnosis, therapy and prescription of biologics
The impact of the first COVID-19 wave on office-based dermatological care in Germany: a focus on diagnosis, therapy and prescription of biologics.
COVID-19
chronic inflammatory skin diseases
biologics
Journal
European journal of dermatology : EJD
ISSN: 1952-4013
Titre abrégé: Eur J Dermatol
Pays: France
ID NLM: 9206420
Informations de publication
Date de publication:
01 04 2022
01 04 2022
Historique:
entrez:
22
7
2022
pubmed:
23
7
2022
medline:
27
7
2022
Statut:
ppublish
Résumé
The COVID-19 pandemic has led to widespread changes in medical care. However, it is still unclear to what extent the care of patients suffering from moderate-to-severe psoriasis, chronic spontaneous urticaria or atopic dermatitis has been affected. This study was conducted to determine the impact of the SARS-CoV-2 pandemic on medical care in dermatological practices, focusing on physicians’ concerns related to susceptibility to infections in combination with different treatment modalities. Dermatologists working in medical offices in the German federal states of Bavaria and Lower Saxony participated in a cross-sectional, non-interventional, questionnaire-based study investigating the influence of COVID-19 on dermatological care. The study was performed after the first wave of the coronavirus pandemic in July/August, 2020. A total of 195 dermatologists participated in the study. Almost one in five practices were closed for at least one week during the pandemic. The care of patients with chronic inflammatory skin diseases was impaired, affecting diagnostic investigation. Physicians stated that the pandemic substantially influenced systemic therapy. Nearly half of physicians surveyed were concerned about increased susceptibility to infections under biological therapy. No significant differences were identified between the German federal states of Bavaria and Lower Saxony in the south and north of Germany, respectively. This study reveals a significant impact of the COVID-19 pandemic on the care of dermatological patients in medical offices in Germany. New management modalities and continuous education are needed to improve care in pandemic situations.
Sections du résumé
Background
The COVID-19 pandemic has led to widespread changes in medical care. However, it is still unclear to what extent the care of patients suffering from moderate-to-severe psoriasis, chronic spontaneous urticaria or atopic dermatitis has been affected.
Objectives
This study was conducted to determine the impact of the SARS-CoV-2 pandemic on medical care in dermatological practices, focusing on physicians’ concerns related to susceptibility to infections in combination with different treatment modalities.
Materials & Methods
Dermatologists working in medical offices in the German federal states of Bavaria and Lower Saxony participated in a cross-sectional, non-interventional, questionnaire-based study investigating the influence of COVID-19 on dermatological care. The study was performed after the first wave of the coronavirus pandemic in July/August, 2020.
Results
A total of 195 dermatologists participated in the study. Almost one in five practices were closed for at least one week during the pandemic. The care of patients with chronic inflammatory skin diseases was impaired, affecting diagnostic investigation. Physicians stated that the pandemic substantially influenced systemic therapy. Nearly half of physicians surveyed were concerned about increased susceptibility to infections under biological therapy. No significant differences were identified between the German federal states of Bavaria and Lower Saxony in the south and north of Germany, respectively.
Conclusion
This study reveals a significant impact of the COVID-19 pandemic on the care of dermatological patients in medical offices in Germany. New management modalities and continuous education are needed to improve care in pandemic situations.
Identifiants
pubmed: 35866899
doi: 10.1684/ejd.2022.4222
pmc: PMC9463962
doi:
Substances chimiques
Biological Products
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
195-206Références
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Acta Derm Venereol. 2019 Mar 1;99(3):263-267
pubmed: 30521060
J Dtsch Dermatol Ges. 2020 Aug;18(8):815-824
pubmed: 32717116
J Am Acad Dermatol. 2008 Jan;58(1):106-15
pubmed: 17936411
Allergy. 2014 Oct;69(10):1275-9
pubmed: 24965386
J Dtsch Dermatol Ges. 2018 May;16(5):645-669
pubmed: 29750443
N Engl J Med. 2016 Dec 15;375(24):2335-2348
pubmed: 27690741
Allergy. 2018 Jul;73(7):1393-1414
pubmed: 29336054
Rheumatology (Oxford). 2019 Oct 1;58(10):1755-1766
pubmed: 30982883
N Engl J Med. 2013 Mar 7;368(10):924-35
pubmed: 23432142
Br J Dermatol. 2021 Jul;185(1):80-90
pubmed: 33368145
J Allergy Clin Immunol. 2021 Jan;147(1):60-71
pubmed: 33075408
Allergo J. 2020;29(4):14-27
pubmed: 32546898
Lancet. 2020 Feb 15;395(10223):470-473
pubmed: 31986257
J Dtsch Dermatol Ges. 2020 Aug;18(8):841-847
pubmed: 32881258
J Eur Acad Dermatol Venereol. 2018 Jun;32(6):850-878
pubmed: 29878606
Lancet. 2019 Sep 7;394(10201):831-839
pubmed: 31402114
World Allergy Organ J. 2020 Sep 12;13(9):100460
pubmed: 32983330
Am J Clin Dermatol. 2019 Jun;20(3):443-456
pubmed: 31066001
Br J Dermatol. 2017 Feb;176(2):495-497
pubmed: 27125261
N Engl J Med. 2020 Nov 12;383(20):1920-1931
pubmed: 32663912
Euro Surveill. 2020 Mar;25(9):
pubmed: 32156327
Allergy. 2021 Oct;76(10):3017-3027
pubmed: 33844308
Acta Derm Venereol. 2020 Jan 30;100(3):adv00032
pubmed: 31971601
N Engl J Med. 2016 Jul 28;375(4):345-56
pubmed: 27299809
J Eur Acad Dermatol Venereol. 2018 May;32(5):657-682
pubmed: 29676534
Allergol Select. 2021 Aug 27;5:293-304
pubmed: 34532638
Allergy. 2021 Mar;76(3):816-830
pubmed: 33284457
Lancet. 2018 Aug 25;392(10148):650-661
pubmed: 30097359
Arch Dermatol Res. 2016 Aug;308(6):389-400
pubmed: 27048503
Dermatol Ther. 2020 Sep;33(5):e13686
pubmed: 32458530
J Invest Dermatol. 2016 Aug;136(8):1584-1591
pubmed: 27085754
Br J Dermatol. 1986 May;114(5):575-82
pubmed: 3718847
N Engl J Med. 2015 Oct;373(14):1318-28
pubmed: 26422722
J Dermatol. 2018 Feb;45(2):150-157
pubmed: 29131384
J Eur Acad Dermatol Venereol. 2018 Jun;32(6):978-984
pubmed: 29356181
Lancet. 2017 Jul 15;390(10091):276-288
pubmed: 28596043
SN Compr Clin Med. 2020;2(11):2126-2130
pubmed: 32935079
Lancet Infect Dis. 2020 Sep;20(9):1012-1013
pubmed: 32251638
Ann Rheum Dis. 2020 Feb;79(2):285-291
pubmed: 31672774
N Engl J Med. 2014 Jul 24;371(4):326-38
pubmed: 25007392
Eur J Dermatol. 2021 Dec 1;31(6):806-812
pubmed: 35107071
Handb Exp Pharmacol. 2022;268:101-115
pubmed: 34236520
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Immunotargets Ther. 2021 Feb 17;10:27-45
pubmed: 33628747
J Dtsch Dermatol Ges. 2018 Jun;16(6):806-813
pubmed: 29873906